Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PER Pulse™ Recaps
for Medical Crossfire®: Integrating CDK4/6 Inhibitors Into the Management of Breast Cancers focus on key topics presented during the program. A brief overview of expert perspectives on areas of clinical challenge faced by practicing oncologists and case management decisions is provided in these summaries.
This activity is supported by an educational grant from Pfizer.
This edition of Medical Crossfire®, filmed in conjunction with the 33rd Annual Miami Breast Cancer Conference®, is designed to provide a dynamic discussion of current and evolving paradigms in the use of CDK inhibition to treat breast cancer, accompanied by discussion of strategies for applying emerging data to clinical practice to improve outcomes for patients.
Our Program Chairs, Debu Tripathy, MD, and Joyce O'Shaughnessy, MD, and our expert faculty, Kimberly Blackwell, MD, and Andrew Seidman, MD, engage in case-based discussions of clinical strategies regarding the use of CDK inhibition, and offer expert perspectives on the latest clinical evidence and practice recommendations, including dose adjustments for adverse-event management.
The activity begins with a 15-minute didactic overview by Dr. Tripathy on treatment algorithms, mechanisms of action of common therapies, relevant key trial data, clinical dilemmas, as well as new drugs and emerging indications. This is followed by a panel discussion about first-line treatment selection, molecular testing, monitoring for treatment response and progression of disease, and adverse-event management. Next, Dr. Blackwell leads a case presentation and panel discussion of a woman with ER-positive, HER2-negative, newly diagnosed, metastatic breast cancer. which is followed by case presentations and extended panel discussion. Finally, Dr. Seidman presents a case and leads the panel in a discussion of a postmenopausal woman with ER-positive, HER2-negative, metastatic breast cancer that has progressed on endocrine therapy. Throughout the activity, interactive online questions are posed to participants to assess knowledge and facilitate self-assessment. The extended discussion format of this activity allows ample time for examining the nuances and challenges faced by clinicians in everyday practice.
Instructions For This Activity & Receiving Credit
This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer may also participate.
Debu Tripathy, MD
Professor and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Joyce A. O'Shaughnessy, MD
Chair, Breast Cancer Research
Celebrating Women Chair in Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
The US Oncology Network
Kimberly L. Blackwell, MD
Professor of Medicine
Assistant Professor of Radiation Oncology
Duke University Medical Center
Andrew D. Seidman, MD
Attending Physician, Breast Cancer Medicine Service
Memorial Sloan Kettering Cancer Center
New York, NY
The following individuals have no relevant financial relationships with commercial interests to disclose:
The staff of Physicians' Education Resource®, LLCThe following individuals have no relevant financial relationships with commercial interests to disclose:
Kimberly L. Blackwell, MD ‒ Grant/Research Support: Celgene, Genentech, Pfizer, Novartis; Consultant: Amgen, Celgene, Eli Lilly, Genentech, Incyte Corporation, Novartis, Pfizer, Roche, Sandoz, Spectrum; Joyce A. O'Shaughnessy, MD – Consultant: Arno Therapeutics, AstraZeneca, Celgene, Corcept, Eisai, Genentech, GSK, Lilly, J&J, Merrimack, Novartis, Pfizer, Roche, Sanofi, Takeda, Medfusion; Andrew D. Seidman, MD ‒ Grant/Research Support: Novartis, Bayer; Consultant: Novartis, Genentech, Merrimack, Kadmon, Pfizer; Speakers Bureau: Celgene, Genomic Health, Novartis, Genentech, Eisai; Debu Tripathy, MD – Grant/Research Support: Novartis; Consultant: Nektar, Novartis, Puma Biotechnology.
It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Oncology Briefings™: Updates in Therapeutic Options and Approaches for Tenosynovial Giant Cell Tumors
Apr 28, 2018
April 28, 2018
New York, NY